EGFR and non-small cell lung carcinoma: Overall, prospective studies and larger molecularly stratified cohorts are required to validate the clinical utility of sequential high-dose third-generation EGFR-TKIs in EGFR ex20ins-mutant NSCLC and to define optimal therapeutic sequencing algorithms.